ARTICLE | Clinical News
Vasogen preclinical data
November 1, 2004 8:00 AM UTC
In a mouse model of PD, VP025 significantly reduced movement abnormalities (p<0.001) and significantly attenuated both the reduction in dopamine and the loss of dopaminergic neurons (p<0.05, for both)...